NCT05571839CompletedPhase 1
A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
Source: EU CTIS (euclinicaltrials.eu) · Last updated 1 Apr 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 45 (actual)
- First submitted
- 14 Apr 2023
- Start date
- 15 Dec 2023
- Lead sponsor
- Seagen Inc.
- NCT number
- NCT05571839
- EU CT number
- 2022-502348-11-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 45
- 5 sites in 3 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (5)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Charite Research Organisation GmbH Coordinator of this site? Confirm its status | Berlin | Germany | Completed |
| National Center for Tumor Diseases (NCT) Heidelberg Coordinator of this site? Confirm its status | Heidelberg | Germany | Completed |
| Institut Gustave Roussy Coordinator of this site? Confirm its status | Villejuif | France | Completed |
| National Cancer Institute Coordinator of this site? Confirm its status | Naples | Italy | Completed |
| Azienda Ospedaliera Universitaria Senese Coordinator of this site? Confirm its status | Siena | Italy | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.